The latest market price of bevacizumab in 2025

Bevacizumab (Bevacizumab) Oncology purposes. As an anti-angiogenesis targeted therapy drug, it has been widely used in the treatment of a variety of malignant tumors, including advanced or metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, cervical cancer, and hepatocellular carcinoma. Bevacizumab is often used in combination with chemotherapy regimens to enhance the overall therapeutic effect and has become an important component of multi-line treatment.

In China, bevacizumab has been approved for marketing by Roche (Roche)'s original product under the trade name "Avastin" and has been included in the national medical insurance directory, covering a variety of indications, significantly reducing the financial burden on patients. Especially in the field of lung cancer and liver cancer treatment, the drug's inclusion in medical insurance has significantly reduced the cost of first-line treatment. The actual price varies depending on local medical insurance. Domestic biosimilar drugs such as Qilu Pharmaceutical’s bevacizumab injection have also obtained marketing approval, further improving drug accessibility.

According to data from overseas drug price platforms, the market price of the experimental version of bevacizumab in the United States is still high. Based on the specifications of 25 mg/mL and 4 mL bottle, the price of a single box is about more than 800 US dollars, and this price does not include medical service costs. In countries such as Singapore and Australia, the drug also maintains high sales prices. It is worth mentioning that although biosimilars have entered the market in many countries, in some regions such as the United States, the launch of true generics of bevacizumab is still relatively lagging behind.

Taken together, bevacizumab has become one of the key biologic drugs in global cancer treatment. Its implementation of domestic medical insurance, price reductions and domestic alternatives have greatly improved clinical accessibility. In overseas markets, original drugs are still a treatment option that is difficult for most patients to afford in the long term due to high costs and limited medical insurance coverage.

Reference materials:https://www.drugs.com/bevacizumab.html